

卡培他滨联合奥沙利铂治疗胃癌的效果分析

赵 敏

开远市人民医院 云南 开远 661600

【摘要】：目的：分析卡培他滨联合奥沙利铂治疗胃癌的效果。方法：选择我院 2021 年 1 月-2022 年 1 月胃癌患者共 57 例，数字表随机分 2 组，对照组 28 例的患者给予顺铂联合 5-氟尿嘧啶化疗治疗，观察组 29 例的患者给予卡培他滨联合奥沙利铂。比较两组治疗前后患者生存质量评分、总有效率、不良反应。结果：观察组治疗后患者生存质量评分高于对照组，总有效率高于对照组， $P < 0.05$ 。观察组不良反应发生率低于对照组， $P < 0.05$ 。结论：卡培他滨联合奥沙利铂治疗胃癌的效果确切，可提高疗效，减少不良反应和提高生存质量。

【关键词】：卡培他滨；奥沙利铂；胃癌；效果

Effect of Capecitabine Combined with Oxaliplatin in the Treatment of Gastric Cancer

Min Zhao

Kaiyuan People's Hospital Yunnan Kaiyuan 661600

Abstract: Objective: To analyze the effect of capecitabine combined with oxaliplatin in the treatment of gastric cancer. Methods: A total of 57 patients with gastric cancer in our hospital from January 2021 to January 2022 were randomly divided into two groups by the number table. 28 patients in the control group were treated with cisplatin combined with 5-fluorouracil chemotherapy, and 29 patients in the observation group were treated with capecitabine combined with oxaliplatin. The quality of life scores, total effective rate and adverse reactions of the two groups were compared before and after treatment. Results: After treatment, the quality of life score of patients in the observation group was higher than that in the control group, and the total effective rate was higher than that in the control group ($P < 0.05$). The incidence of adverse reactions in the observation group was lower than that in the control group ($P < 0.05$). Conclusion: Capecitabine combined with oxaliplatin is effective in the treatment of gastric cancer, which can improve the efficacy, reduce adverse reactions and improve the quality of life.

Keywords: Capecitabine; Oxaliplatin; Gastric cancer; Effect

1 资料与方法

1.1

				2021	1	- 2022	1		57
				2			28	17	11
				31- 78	56.12± 2.21		29	18	
⁰¹	20	60	5-	11	32- 76	56.21± 2.24			
				P	0.05				
					6				
			5-		1				
					2			3	
			5-		4				
					1.2				
			5-				5-		
					20mg/m ²				
			5-		200mg/m ²				
					5-		5-		2400mg/m ²

1 21 3
 2
 1250mg/m² 1
 5% 85mg/m² 1 21
 3

	2 9	6(20.7)	12(41.4)	8(27.9)	3(10.3)	18(62.1)
X ²						10.54
P						0.05

23

P 0.05

1.3

1.4

1.5

SPSS22.0

x²

t

P 0.05

	28	4(14.3)	2(7.1)	1(3.6)	2(7.1)	9(32.1)
	29	1(3.4)	0(0.0)	1(3.4)	1(3.4)	3(10.3)
X ²						10.71
P						0.05

3 讨论

2 结果

21

P 0.05

P 0.05

1

1

$\bar{x} \pm s$

		67.56 ± 4.81	65.37± 2.56	67.56± 4.87	67.37± 5.36
		92.12 ± 6.94	93.21± 5.23	93.12± 4.94	93.21± 5.56
		67.53 ± 4.78	65.35± 2.56	67.34± 4.81	67.45± 5.31
		82.45 ± 6.12	83.21± 4.12	83.45± 4.34	82.55± 5.12

22

P 0.05

2

2

[%]

	2 8	5(17.9)	8(28.6)	14(50.0)	5(17.9)	13(46.5)

50

1

60-80

2

3

4

5

6

7

8

9

[3-4]

[5-6]

3

DNA DNA G DNA P 0.05

参考文献:

[1] . [J]. ,2022, 15(25):97- 100.

[2] , 炆 . [J]. , 2022,15(23):69- 72.

[3] . [J]. ,2022,38(18):22- 24+27.

[4] . [J]. ,2022,22(11):22- 24+42.

[5] . [J]. ,2022,19(11):677- 680.

[6] . [J]. ,2022,15(12):90- 93.

[7] . [J]. ,2022, 25(03):217- 220.

	5 - -5-	5 - -5-	Cma	AUC	Cm	AUC	31%	AUC
60%							84%	12
					3%	2.6%		
					5- FU			5- FU
								5- FU

P 0.05